Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Institute for the Study of Aging (ISOA) Pfizer |
---|---|
Information provided by: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00024531 |
The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.
Condition | Intervention | Phase |
---|---|---|
Alzheimer Disease |
Drug: Atorvastatin calcium |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study |
Official Title: | Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's Disease |
Estimated Enrollment: | 98 |
Study Start Date: | October 2000 |
Estimated Study Completion Date: | August 2004 |
This study is a phase II, placebo controlled, double-blind, one year trial investigating the effect of HmG-CoA reductase inhibitor atorvastatin calcium in the treatment of persons with possible or probable Alzheimer's disease. Subjects may continue to take stable doses of Aricept and Exelon. Following enrollment, participants will make visits to the study center every three months for blood tests and neuropsychological testing.
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Individuals taking stable doses of other cholinesterase inhibitors can be included, but no study subject may initiate use of any cholinesterase inhibitor after entrance to trial.
Exclusion criteria:
United States, Arizona | |
Sun Health Research Institute | |
Sun City, Arizona, United States, 85351 |
Principal Investigator: | David L Sparks, PhD | Sun Health Research Institute |
Study ID Numbers: | IA0031 |
Study First Received: | September 19, 2001 |
Last Updated: | November 8, 2006 |
ClinicalTrials.gov Identifier: | NCT00024531 History of Changes |
Health Authority: | Unspecified |
Alzheimer disease Cholesterol-lowering drugs |
Antimetabolites Antilipemic Agents Alzheimer Disease Central Nervous System Diseases Anticholesteremic Agents Brain Diseases Neurodegenerative Diseases Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Cognition Disorders Calcium, Dietary Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Dementia Atorvastatin Delirium |
Antimetabolites Molecular Mechanisms of Pharmacological Action Antilipemic Agents Alzheimer Disease Nervous System Diseases Central Nervous System Diseases Enzyme Inhibitors Anticholesteremic Agents Brain Diseases |
Neurodegenerative Diseases Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Therapeutic Uses Dementia Tauopathies Atorvastatin |